Nelitolimod (SD-101) via PEDD™ PRVI + systemic checkpoint inhibitors
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Key Facts
Indication
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Phase
Phase 1
Status
Recruiting participants
Company
About TriSalus Life Sciences
TriSalus Life Sciences is a public, clinical-stage biotech focused on overcoming the anatomical and biological barriers that render liver and pancreatic tumors resistant to treatment. Its core strategy integrates two proprietary components: the Pressure-Enabled Drug Delivery (PEDD™) method, which uses FDA-cleared catheter devices to enhance intravascular drug delivery, and nelitolimod (SD-101), a TLR9 agonist designed to reprogram the immunosuppressive tumor microenvironment. The company is advancing multiple Phase 1/2 trials, aiming to validate its platform and create new standards of care for some of oncology's most challenging solid tumors.
View full company profile